RankAlpha logo
Back to Rankings

ALGS

Aligos TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
View Chart
Current thesis
The post-earnings update was incrementally better than the April baseline: B-SUPREME remains active after clearing futility, the Amoytop transaction adds a $25 million upfront cash component, and management now guides runway into the fourth quarter of 2026 rather than only into the third quarter. That supports a monitoring thesis instead of a fresh deterioration call.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Management said current cash is expected to fund operations only into the fourth quarter of 2026, inclusive of the expected Amoytop upfront, leaving a financing or partnering need ahead of 2027 topline data [#8-K-2026-05-07].
Momentum
65
Value
58
Sentiment
58
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.80 · Bull $10.00 · Bear $3.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $54.88
Why
Momentum65 · Δ7d -
Value58 · Δ7d +0.1
Sentiment58 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
65
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.1
Sentiment
58
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade B. Momentum 65.5 / Value 58.5 / Sentiment 57.7

Fundamentals (TTM)
As of 2026-07-21
Market Cap
$33.66M
Beta
2.67
Shares Out
6.19M
P/E (TTM) · Derived
-2.2
P/S (TTM)
19.56
P/FCF (TTM) · Derived
-0.66
Rev YoY
+810.0%
EPS YoY
+4.8%
Gross Margin
+77.0%
Op Margin
-3277.9%
Net Debt
-$72.7M
Current Ratio
2.56
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology